Latest gastrointestinal stromal tumor Stories
- On track to file INDs for BLU-285 and initiate clinical studies in mid-2015 - CAMBRIDGE, Mass., April 19, 2015 /PRNewswire/ -- Blueprint Medicines today announced new preclinical data demonstrating
CAMBRIDGE, Mass., April 8, 2015 /PRNewswire/ -- Blueprint Medicines today announced it will present new preclinical data on its drug candidate BLU-285 in gastrointestinal stromal tumors (GIST), as
Research Presented at 2015 Gastrointestinal Cancers Symposium Highlights Clinical Utility of Caris Molecular Intelligence IRVING, Texas, Jan.
Significant Opportunity Exists for New Therapies to Treat GIST, Particularly those for Treating Unresectable and/or Metastatic Disease in Later-Line Settings BURLINGTON, Mass., Aug.
- Awareness campaign aims to break world record for largest display of origami boats to show widespread support for GIST community WHIPPANY, N.J.
LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
WHIPPANY, N.J., Feb.
- A serpent whose bite was fabled to produce intense thirst.